In this month’s What’s Hot in Parkinson’s disease? column, I review what is becoming a hot topic: a Sinemet shortage. Recently, many people with Parkinson’s disease (PD) have been informed by their pharmacy that there is a shortage of Sinemet or that their brand of Sinemet has been “discontinued.” What should you do?
In this week’s issue of Science Translational Medicine, Bryan Killinger, PhD, and colleagues examined the question, “Will removing my appendix impact my risk of later developing Parkinson’s disease (PD)?”
Interestingly, several recent studies have attempted to answer this question. With the emerging evidence supporting that a gut-brain connection and interaction may play a potential role in Parkinson’s, this subject is a timely one.
The microbiome is a hot topic in Parkinson’s disease (PD). The microbiome is the network of microorganisms, along with viruses and bacteria, that help the body stay healthy. In the PD community, when we talk about the microbiome, we’re referring to the bacteria found in the gut. Leading experts have suggested that the microbiome has a potential role in the pathogenesis (way a disease develops) and in the treatment of Parkinson’s. This has sparked the idea that we might be able to improve PD symptoms if we change the microbiome through diet or other ways.
Though dizziness and vertigo have been commonly reported in the setting of Parkinson’s disease (PD), the diagnosis may be missed and treatment may not be optimal. The terms dizziness and vertigo can be defined in many ways. Most experts agree that the terms refer to a sensation of spinning or whirling and that the sensation has been frequently associated with balance problems.
Maintaining cognitive brain health is a high priority for both people with Parkinson’s disease (PD) and family members. Though many living with Parkinson’s will not develop dementia, mild cognitive issues may emerge in 20 to 50 percent.
We always advise patients to ask their doctor what’s new in Parkinson’s disease (PD). Recently, three leading experts at the Parkinson’s Foundation Center Leadership Conference reviewed the field and updated all attendees on several of the exciting therapies currently being tested by Albert Hung, MD, PhD, Massachusetts General Hospital (MGH); Irene Richard, MD, University of Rochester Medical Center; and Hubert Fernandez, MD, Cleveland Clinic. In this month’s What’s Hot in PD blog we review their latest therapies.
A recent study by Inga and colleagues at the Mount Sinai Beth Israel Parkinson’s Foundation Center of Excellence in New York examined the incidence of Parkinson’s disease in inflammatory bowel disease patients. The authors were also interested as to whether exposure to anti-tumor necrosis factor therapy (anti-TNF) could possibly reduce the risk of the later development of Parkinson’s disease.
The recent forecasting estimates for Parkinson’s disease (PD) are staggering. If accurate, the numbers suggest an urgent need to wake up and recognize that we are on the cusp of an emerging pandemic (Okun, 2013).
An epidemic is a widespread occurrence of an infectious disease, usually in a community and typically during a particular timeframe. A pandemic is a disease that is prevalent over an entire country or worldwide. The increase in the global number of people living with Parkinson’s should therefore appropriately be termed a pandemic.
Parkinson’s disease (PD) specialists have long debated the potential value of Parkinson’s-specific physical therapy. All great medical debates are usually settled by two factors: time and data. In this month’s What’s Hot, we review a paper recently published in Lancet Neurology (Ypinga 2018) that provides insight and data for whether people with Parkinson’s should begin or continue specialized physiotherapy.